Metraipolis › archive › dc_a69080af5828

Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States — Europe PMC PMID:38060500

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/38060500
DOI
10.1371/journal.pone.0294164
License (as archived)
CC0-1.0
Archived
2026-10-07T11:30:42.415Z
SHA-256 of the archived text
bbbfd2e06ca6d1dc09aa249cad7186b536b37d969f154a9cbfb6c9dd7567bdda
Stable URL of this page
https://metraipolis.com/documento/dc_a69080af5828

How to cite

Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States — Europe PMC PMID:38060500 — Europe PMC (en), https://europepmc.org/article/MED/38060500 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_a69080af5828 (Metraipolis archive dc_a69080af5828, sha256 bbbfd2e06ca6d1dc09aa249cad7186b536b37d969f154a9cbfb6c9dd7567bdda)
BibTeX
@misc{dca69080af5828,
  title = {Pharmacy and neighborhood-level variation in cash price of diabetes medications in the United States — Europe PMC PMID:38060500},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/38060500},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_a69080af5828; sha256 bbbfd2e06ca6d1dc09aa249cad7186b536b37d969f154a9cbfb6c9dd7567bdda},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/38060500. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

Background: Diabetes medications place significant financial burden on patients but less is known about factors affecting cost variation. Objective: To examine pharmacy and neighborhood factors associated with cost variation for diabetes drugs in the US. Research design, subjects and measures: We used all-payer US pharmacy data from 45,874 chain and independent pharmacies reflecting 7,073,909 deidentified claims. We divided diabetes drugs into insulins, non-insulin generic medications, and brand name medications. Generalized linear models, stratified by pharmacy type, identified pharmacy and neighborhood factors associated with higher or lower cash price-per-unit (PPU) for each set of drugs. Results: Cash PPU was highest for brand name therapies ($149.4±203.2), followed by insulins ($42.4±25.0), and generic therapies ($1.3±4.4). Pharmacy-level price variation was greater for non-insulin generic therapies than insulins or brand name therapies. Chain pharmacies had both lower prices and lesser variation compared with independent pharmacies. Conclusions: Cash prices for diabetes medications in the US can vary considerably and that the greatest degree of price variation occurs in non-insulin generic therapies.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PloS one, 2023 (prima pubblicazione 2023-12-07).
Identificativi: PMID 38060500 · PMCID PMC10703254 · DOI 10.1371/journal.pone.0294164.
Descrittori MeSH principali: Diabetes Mellitus; Pharmacy; Pharmacies; Insulins.
Pagina: https://europepmc.org/article/MED/38060500 — https://doi.org/10.1371/journal.pone.0294164. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-07T11:17:30.997Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.